PUBLISHER: The Business Research Company | PRODUCT CODE: 2106457
PUBLISHER: The Business Research Company | PRODUCT CODE: 2106457
Senolytic and anti-aging therapeutics represent a category of treatments intended to selectively remove senescent, aging, or dysfunctional cells, or to slow the biological mechanisms associated with aging. These therapies are designed to enhance tissue performance and promote healthier longevity by decreasing cellular deterioration and chronic inflammation linked to aging. Their purpose is to support improved physiological function and extend healthspan.
The primary drug classes of senolytic and anti-aging therapeutics comprise senolytics, senomorphics, nicotinamide adenine dinucleotide precursors, and mechanistic target of rapamycin inhibitors. Senolytics are therapeutic agents developed to selectively remove senescent cells that drive aging and age-related disorders. These therapies are classified into treatment modalities such as small molecule therapy, biologic therapy, gene therapy, and immunotherapy, and are delivered via oral, injectable, topical, and implantable routes. The various applications covered include cardiovascular disease, frailty and musculoskeletal aging, neurodegeneration, and ophthalmology, and they are utilized by multiple end users such as academic medical centers, geriatric clinics, consumer wellness providers, and clinical research organizations.
Tariffs are influencing the senolytic and anti-aging therapeutics market by increasing costs of imported biologics, active pharmaceutical ingredients, laboratory reagents, and advanced research equipment essential for drug development and clinical validation. This is slowing R&D timelines and raising operational expenses, particularly in biotech-intensive regions such as North America and Europe that depend on Asia-Pacific supply chains for raw materials and precision laboratory components. Drug classes such as senolytics and mTOR inhibitors, along with therapy types like biologics and gene therapies, are most affected due to reliance on complex manufacturing inputs. However, tariffs are also encouraging regional manufacturing expansion, domestic biotech investment, and supply chain diversification, ultimately strengthening long-term resilience and innovation capacity in the anti-aging therapeutics ecosystem.
The senolytic and anti-aging therapeutics market size has grown rapidly in recent years. It will grow from $2.18 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to increasing incidence of age-related degenerative conditions, limited effectiveness of traditional regenerative therapies, expanding global elderly population, rising funding for cellular senescence research, and growing number of early-stage biotechnology longevity startups.
The senolytic and anti-aging therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The forecast period growth can be attributed to advancements in therapies targeting senescent cell elimination, integration of artificial intelligence in drug discovery for anti-aging, expansion of personalized treatment approaches in geriatric care, increasing demand for preventive healthcare solutions, and growing clinical validation of senolytic therapies. Major trends include development of geroscience-driven drug discovery pipelines, emergence of senescence biomarker-based diagnostics, advancement of precision longevity treatments, adoption of preventive anti-aging healthcare models, and combination therapies involving senolytic and senomorphic approaches.
The increasing aging population is expected to propel the growth of the senolytic and anti-aging therapeutics market going forward. An aging population refers to a population in which the proportion of elderly people is higher than the proportion of younger people. An increasing aging population is primarily due to rising life expectancy, as people are living longer and more individuals are reaching older age groups. Senolytic and anti-aging therapeutics support aging populations by targeting cellular senescence, reducing age-related diseases, enhancing tissue regeneration, and promoting healthier longevity outcomes. For instance, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of people aged 60 years and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the increasing aging population is driving the growth of the senolytic and anti-aging therapeutics market.
Leading companies operating in the senolytic and anti-aging therapeutics market are focusing on the development of innovative platforms such as senolytic immunotherapy platforms to target and eliminate senescent cells, thereby addressing underlying biological mechanisms of aging, chronic inflammation, and age-related diseases. Senolytic immunotherapy is a treatment approach that combines immune system activation with senolytic strategies to selectively identify and remove senescent (aged and non-functioning) cells from the body, helping restore tissue function, improve cellular health, and potentially slow degenerative processes associated with aging compared to conventional symptom-focused therapies. For example, in November 2025, Immorta Bio Inc., a US-based biotechnology company, announced the publication of an international patent application for SenoVax, a first-in-class senolytic immunotherapy designed to train the immune system to recognize and clear senescent cells more effectively. The therapy is engineered to stimulate targeted immune responses against aging cells, aiming to reduce chronic inflammation, improve regenerative capacity, and support healthier tissue function across multiple age-related conditions. By combining immunotherapeutic mechanisms with senolytic targeting, SenoVax represents an advanced approach in longevity science focused on addressing the root causes of biological aging rather than only managing its symptoms.
In May 2025, Altos Labs Inc., a US-based biotechnology firm, completed the acquisition of Dorian Therapeutics for an undisclosed valuation. Through this acquisition, Altos Labs intends to enhance its research capabilities in cellular rejuvenation and longevity by incorporating Dorian Therapeutics' senescence-targeting technologies along with its preclinical therapeutic programs aimed at age-related disorders. Dorian Therapeutics Inc. is a US-based biotechnology company focused on developing senolytic and anti-aging therapies, particularly a novel drug class referred to as senoblockers.
Major companies operating in the senolytic and anti-aging therapeutics market are AbbVie Inc., Alkahest Inc., Altos Labs Inc., BlueRock Therapeutics, Calico Life Sciences LLC, Cambrian BioPharma Inc., Celularity Inc., Eli Lilly and Company, Elevian, Elysium Health Inc., Eos SENOLYTIX Inc., Gero PTE. LTD., HexemBio Inc., Insilico Medicine Inc., Juvenescence Limited, Life Biosciences Inc., Merck & Co. Inc., Novartis AG, Oisin Biotechnologies Inc., Pfizer Inc., Retro Biosciences Inc., Rubedo Life Sciences Inc., Stealth BioTherapeutics, UNITY Biotechnology Inc.
North America was the dominant region in the senolytic and anti-aging therapeutics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in senolytic and anti-aging therapeutics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the senolytic and anti-aging therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The senolytic and anti-aging therapeutics market consists of sales of senolytic agents, senomorphic drugs, and anti-aging pharmaceuticals. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or developers of the therapies, whether to other entities (including hospitals, research institutes, distributors, pharmacies, wellness centers, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The senolytic and anti-aging therapeutics market research report is one of a series of new reports from The Business Research Company that provides senolytic and anti-aging therapeutics market statistics, including senolytic and anti-aging therapeutics industry global market size, regional shares, competitors with a senolytic and anti-aging therapeutics market share, detailed senolytic and anti-aging therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the senolytic and anti-aging therapeutics industry. This senolytic and anti-aging therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Senolytic And Anti-Aging Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses senolytic and anti-aging therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for senolytic and anti-aging therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The senolytic and anti-aging therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.